For long-term survivors of childhood cancer treated with doxorubicin, the improvements in left ventricular (LV) function and structure at first seen with enalapril diminish over time, researchers report.
Dr. Steven E. Lipshultz from the University of Rochester Medical Center, New York, and colleagues reviewed the records of 18 children who had been diagnosed with cancer at a mean age of 8 years and were treated with doxorubicin.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!